With scarce clinical resources unable to keep pace with elevated rates of mental illness, technological solutions could help decrease waitlists and disparities in access to therapy. Recent advances in artificial intelligence ...
May 17, 2023
0
66
Resistance to HER2-targeted therapies can be a problem when treating patients with HER2-positive (HER2+) breast cancer. Therefore, the identification of new therapies for this patient group is important. Researchers at the ...
Mar 14, 2023
0
26
The hormone kisspeptin could be used to treat women and men distressed by their low sexual desire, according to two new studies.
Feb 3, 2023
1
44
Artificial intelligence technology has tripled the number of UK stroke patients recovering to a point where they can perform daily activities, according to new research released on Tuesday.
Dec 27, 2022
0
43
Ketamine, an established anesthetic and increasingly popular antidepressant, dramatically reorganizes activity in the brain, as if a switch had been flipped on its active circuits, according to a new study by Penn Medicine ...
Dec 1, 2022
1
888
Deep brain stimulation (DBS) to the superolateral branch of the medial forebrain bundle (MFB), which is linked to reward and motivation, revealed metabolic brain changes over 12 months post-DBS implantation, making it a strong ...
Aug 19, 2022
0
181
Researchers have identified a gene that promotes muscle strength when switched on by physical activity, unlocking the potential for the development of therapeutic treatments to mimic some of the benefits of working out.
Jul 25, 2022
0
92
For the first time, researchers have shown what happens to the brain when a person receives a depression treatment known as repetitive transcranial magnetic stimulation (rTMS). The results were published today in the American ...
May 18, 2022
0
95
Psilocybin, the psychedelic compound found in magic mushrooms, helps to "open up" depressed people's brains, even after use, enabling brain regions to talk more freely to one another.
Apr 11, 2022
7
253
The antiviral therapies remdesivir, molnupiravir, and the active ingredient in Pfizer's Paxlovid pill (nirmatrelvir), remain effective in laboratory tests against the BA.2 variant of SARS-CoV-2, the virus that causes COVID-19.
Mar 10, 2022
0
123
